NL300996I2 - Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout - Google Patents
Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout Download PDFInfo
- Publication number
- NL300996I2 NL300996I2 NL300996C NL300996C NL300996I2 NL 300996 I2 NL300996 I2 NL 300996I2 NL 300996 C NL300996 C NL 300996C NL 300996 C NL300996 C NL 300996C NL 300996 I2 NL300996 I2 NL 300996I2
- Authority
- NL
- Netherlands
- Prior art keywords
- naldemedine
- solvate
- salt
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- AXQACEQYCPKDMV-RZAWKFBISA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-n-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C(O)=C(C[C@]2(O)[C@]34CC1)C(=O)NC(C)(C)C=1ON=C(N=1)C=1C=CC=CC=1)CC1CC1 AXQACEQYCPKDMV-RZAWKFBISA-N 0.000 title 1
- 229950002907 naldemedine Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 125000005490 tosylate group Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005151864 | 2005-05-25 | ||
| JP2006065762 | 2006-03-10 | ||
| PCT/JP2006/310231 WO2006126529A1 (ja) | 2005-05-25 | 2006-05-23 | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| PCT/JP2006/310454 WO2006126637A1 (ja) | 2005-05-25 | 2006-05-25 | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300996I1 NL300996I1 (nl) | 2019-07-03 |
| NL300996I2 true NL300996I2 (nl) | 2019-07-30 |
Family
ID=37451954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300996C NL300996I2 (nl) | 2005-05-25 | 2019-06-26 | Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8084460B2 (Direct) |
| EP (1) | EP1889848B8 (Direct) |
| JP (1) | JP4323547B2 (Direct) |
| KR (1) | KR100912782B1 (Direct) |
| CN (1) | CN101228172B (Direct) |
| AU (1) | AU2006250390B2 (Direct) |
| BE (1) | BE2019C533I2 (Direct) |
| BR (1) | BRPI0610343B8 (Direct) |
| CA (1) | CA2609733C (Direct) |
| DK (1) | DK1889848T3 (Direct) |
| ES (1) | ES2525215T3 (Direct) |
| FR (1) | FR19C1042I2 (Direct) |
| HU (1) | HUS1900034I1 (Direct) |
| MX (1) | MX2007014588A (Direct) |
| NL (1) | NL300996I2 (Direct) |
| PL (1) | PL1889848T3 (Direct) |
| PT (1) | PT1889848E (Direct) |
| RU (1) | RU2403255C2 (Direct) |
| TW (1) | TWI311056B (Direct) |
| WO (2) | WO2006126529A1 (Direct) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| CA2905541C (en) * | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| JP5252391B2 (ja) * | 2008-02-21 | 2013-07-31 | 学校法人北里研究所 | オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途 |
| CA2734333A1 (en) * | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
| BR112012006069A8 (pt) * | 2009-09-18 | 2017-10-10 | Adolor Corp | Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto |
| US20130217672A1 (en) * | 2010-05-13 | 2013-08-22 | Green Cross Corporation | (+)-3-hydroxymorphinan-based polycycle derivatives |
| US9108975B2 (en) | 2010-11-12 | 2015-08-18 | Shionogi & Co., Ltd. | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
| US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
| CN110325178B (zh) * | 2016-12-26 | 2022-05-13 | 盐野义制药株式会社 | 改善含量均一性的制剂的制造方法 |
| MA52249A (fr) | 2018-04-12 | 2021-05-05 | Morphic Therapeutic Inc | Antagonistes de l'intégrine humaine (alpha4) (beta7) |
| KR102201609B1 (ko) | 2019-04-19 | 2021-01-12 | 연성정밀화학(주) | 날데메딘의 제조방법 |
| ES3035561T3 (en) | 2019-10-16 | 2025-09-04 | Morphic Therapeutic Inc | Inhibiting human integrin alpha4beta7 |
| EP4062973A4 (en) | 2019-11-20 | 2023-11-29 | Shionogi & Co., Ltd | 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation |
| CN111905111B (zh) * | 2020-09-16 | 2023-03-31 | 地奥集团成都药业股份有限公司 | 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法 |
| IT202300009864A1 (it) * | 2023-05-16 | 2024-11-16 | Procos Spa | Processo per la preparazione di naldemedina |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272541A (en) | 1978-06-02 | 1981-06-09 | Miles Laboratories, Inc. | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them |
| US4275205A (en) | 1980-05-05 | 1981-06-23 | Miles Laboratories, Inc. | 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols |
| US4347361A (en) | 1980-12-10 | 1982-08-31 | Sisa, Incorporated | 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds |
| US4370333A (en) | 1981-06-29 | 1983-01-25 | Sisa, Incorporated | 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it |
| US4443605A (en) | 1982-07-30 | 1984-04-17 | Miles Laboratories, Inc. | 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans |
| US4440932A (en) | 1982-09-09 | 1984-04-03 | Miles Laboratories, Inc. | 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans |
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| WO1995003308A1 (fr) | 1993-07-23 | 1995-02-02 | Toray Industries, Inc. | Derive de morphinane et application medicale |
| US5464841A (en) | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
| KR19990077125A (ko) | 1996-01-10 | 1999-10-25 | 파올로 비지, 엔리꼬 카쭐라니 | 헤테로고리-축합 모르핀 유도체 (ⅱ) |
| WO2001002375A1 (en) | 1999-07-01 | 2001-01-11 | Chemrx Advanced Technologies, Inc. | Process for synthesizing oxadiazoles |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| AU784541B2 (en) * | 1999-11-29 | 2006-04-27 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| US20040024004A1 (en) | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| EP1284736A2 (en) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
| WO2001085150A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists |
| ES2239170T3 (es) * | 2000-10-31 | 2005-09-16 | Rensselaer Polytechnic Institute | 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides. |
| JP4292738B2 (ja) * | 2000-11-22 | 2009-07-08 | 東レ株式会社 | インドール誘導体およびその医薬用途 |
| ATE466016T1 (de) * | 2001-08-23 | 2010-05-15 | Organon Nv | Verfahren for zur herstellung eines 14- hydroxynormorphinon-derivats |
| DE10161963A1 (de) | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| DE10229842A1 (de) * | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| EP1522542A1 (en) * | 2002-07-11 | 2005-04-13 | Toray Industries, Inc. | Therapeutic or preventive agent for nausea/vomiting |
| AU2003299045A1 (en) * | 2002-09-18 | 2004-04-08 | The Curators Of The University Of Missouri | OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR |
| US20040157784A1 (en) | 2003-02-10 | 2004-08-12 | Jame Fine Chemicals, Inc. | Opiod tannate compositions |
| WO2005105093A2 (en) | 2003-08-26 | 2005-11-10 | Duke University | METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION |
| US8481501B2 (en) | 2004-05-28 | 2013-07-09 | Human Biomolecular Research Institute | Synthesis of metabolically stable analgesics, pain medications and other agents |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| US7142420B2 (en) | 2004-09-20 | 2006-11-28 | Qualcomm, Incorporated | Devices and methods for controlling relative movement between layers of an electronic device |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| US9108975B2 (en) | 2010-11-12 | 2015-08-18 | Shionogi & Co., Ltd. | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
-
2006
- 2006-05-23 WO PCT/JP2006/310231 patent/WO2006126529A1/ja not_active Ceased
- 2006-05-24 TW TW095118443A patent/TWI311056B/zh active
- 2006-05-25 ES ES06746833.0T patent/ES2525215T3/es active Active
- 2006-05-25 DK DK06746833.0T patent/DK1889848T3/en active
- 2006-05-25 PL PL06746833T patent/PL1889848T3/pl unknown
- 2006-05-25 CA CA2609733A patent/CA2609733C/en active Active
- 2006-05-25 WO PCT/JP2006/310454 patent/WO2006126637A1/ja not_active Ceased
- 2006-05-25 BR BRPI0610343A patent/BRPI0610343B8/pt not_active IP Right Cessation
- 2006-05-25 CN CN2006800271187A patent/CN101228172B/zh active Active
- 2006-05-25 US US11/920,851 patent/US8084460B2/en not_active Ceased
- 2006-05-25 EP EP06746833.0A patent/EP1889848B8/en active Active
- 2006-05-25 US US15/064,511 patent/USRE46365E1/en active Active
- 2006-05-25 PT PT67468330T patent/PT1889848E/pt unknown
- 2006-05-25 MX MX2007014588A patent/MX2007014588A/es active IP Right Grant
- 2006-05-25 RU RU2007148412/04A patent/RU2403255C2/ru active
- 2006-05-25 AU AU2006250390A patent/AU2006250390B2/en not_active Ceased
- 2006-05-25 JP JP2007517895A patent/JP4323547B2/ja active Active
-
2007
- 2007-11-23 KR KR1020077027287A patent/KR100912782B1/ko active Active
-
2011
- 2011-11-30 US US13/308,483 patent/US8536192B2/en not_active Ceased
-
2016
- 2016-03-08 US US15/064,538 patent/USRE46375E1/en active Active
-
2019
- 2019-06-20 FR FR19C1042C patent/FR19C1042I2/fr active Active
- 2019-06-24 BE BE2019C533C patent/BE2019C533I2/nl unknown
- 2019-06-26 NL NL300996C patent/NL300996I2/nl unknown
- 2019-07-03 HU HUS1900034C patent/HUS1900034I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300996I1 (nl) | Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout | |
| NL301261I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| NL301150I2 (nl) | setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301037I2 (nl) | Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan | |
| NL301042I1 (nl) | Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301049I1 (nl) | Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301020I2 (nl) | Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat | |
| FIC20240039I1 (fi) | Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| NL300974I2 (nl) | Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat | |
| NL301104I2 (nl) | Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat. | |
| NO2021018I1 (no) | kabotegravir eller et farmasøytisk akseptabelt salt eller solvat derav | |
| NL301106I1 (nl) | Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301057I2 (nl) | Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NL300990I2 (nl) | Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan | |
| NL300913I2 (nl) | Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride | |
| NL300887I2 (nl) | Tofacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder tofacitinibcitraat | |
| NL300865I2 (nl) | Eluxadoline of een farmaceutisch aanvaardbaar zout ervan | |
| DK1963369T3 (da) | Il-21-antagonister | |
| FR2876829B1 (fr) | Le tableau anime multisensoriel | |
| EP1852117A4 (en) | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN | |
| ATE386163T1 (de) | Gleisbaumaschine | |
| FI20041392A0 (fi) | Hitsauslaite | |
| ES1056962Y (es) | Maquina para la fabricacion en obra de cunetas de hormigon. | |
| DE502004005704D1 (de) | Dispersionen |